Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells

Protein Eng. 1991 Apr;4(4):463-8. doi: 10.1093/protein/4.4.463.

Abstract

We have used site-directed insertion and point mutagenesis in an attempt to increase the cytotoxic potency and receptor-binding affinity of the diphtheria-toxin-related interleukin-2 (IL-2) fusion toxins. Previous studies have demonstrated that both the DAB486-IL-2 and DAB389-IL-2 forms of the fusion toxin consist of three functional domains: the N-terminal fragment-A-associated ADP-ribosyltransferase, the hydrophobic-membrane-associating domains, and the C-terminal receptor-binding domain of human IL-2. By insertion mutagenesis we have increased the apparent flexibility of the polypeptide chain between the membrane-associating domains and the receptor-binding domain of this fusion toxin. In comparison to DAB486-IL-2, the cytotoxic potency of the insertion mutants was increased by approximately 17-fold for high-affinity IL-2-receptor-bearing cell lines in vitro. Moreover, competitive displacement experiments using [125I]rIL-2 demonstrate that the increase in cytotoxic potency correlates with an increase in receptor-binding affinity for both the high and intermediate forms of the IL-2 receptor.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Base Sequence
  • Binding, Competitive
  • Cell Line
  • Cell Survival / drug effects
  • Diphtheria Toxin / genetics*
  • Diphtheria Toxin / isolation & purification
  • Diphtheria Toxin / metabolism
  • Diphtheria Toxin / pharmacology
  • Humans
  • Interleukin-2 / genetics*
  • Interleukin-2 / isolation & purification
  • Interleukin-2 / metabolism
  • Interleukin-2 / pharmacology
  • Molecular Sequence Data
  • Mutagenesis, Insertional
  • Mutagenesis, Site-Directed
  • Protein Binding
  • Protein Conformation
  • Protein Engineering*
  • Receptors, Interleukin-2 / metabolism*
  • Recombinant Fusion Proteins / isolation & purification
  • Recombinant Fusion Proteins / metabolism
  • Recombinant Fusion Proteins / pharmacology*
  • Software

Substances

  • Diphtheria Toxin
  • Interleukin-2
  • Receptors, Interleukin-2
  • Recombinant Fusion Proteins